Clinical Trial Update: Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of FluBHPVE6E7 in HPV16-infected women is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• FluBHPVE6E7

Snippet

Sponsor: BlueSky Immunotherapies GmbH | Conditions: HPV Infection, HPV-Related Cervical Carcinoma | Phase 1 | Status: RECRUITING